Targeting Trop2 in solid tumors: a look into structures and novel epitopes

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Trophoblast cell surface antigen 2 (Trop2) is highly expressed in various solid tumors but minimally in normal tissues.
• Anti-Trop2 antibody-drug conjugates (ADCs) show efficacy in breast cancer, validating Trop2 as a therapeutic target.
• Current ADCs face challenges with toxicity and response rates, necessitating improved therapeutic strategies for Trop2-positive cancers.

Purpose of the Study:

• To review recent advances in understanding Trop2's structure and dynamic attributes.
• To provide an overview of epitope characteristics for Trop2-targeted agents.
• To discuss the relationship between anti-Trop2 agent epitopes and their therapeutic functions, efficacy, and specificity.

Main Methods:

• Literature review of recent advancements in Trop2 research.
• Analysis of structural attributes and oligomeric assembly of Trop2.
• Examination of epitope characteristics of existing Trop2-targeted agents.

Main Results:

• Trop2's complex structure and oligomeric assembly present challenges for targeted therapies.
• Understanding Trop2 epitopes is crucial for developing effective and specific anti-Trop2 agents.
• The correlation between epitopes and agent function highlights potential for optimizing targeted therapy efficacy.

Conclusions:

• Trop2 remains a promising target for cancer therapy, particularly in Trop2-positive cancers.
• Further research into Trop2's structural dynamics and epitope mapping is essential for advancing targeted therapeutics.
• Optimizing anti-Trop2 agents based on epitope characteristics can potentially overcome current limitations in efficacy and toxicity.